Search
中/EN
Contact/Message
Home
central pharmacy
Policies
Medical Institution
Franchise
Innovate
Recruit
News
Search
Home
central pharmacy
Policies
Medical Institution
Franchise
Innovate
Recruit
News
中/EN
Contact/Message
Innovate
Your current position:
Home
Innovate
International innovative drugs
TZIELD (teplizumab-mzwv)
TZIELD (teplizumab-mzwv)
departments:
内科
drug:
注射剂
Active:
teplizumab-mzwv
indication:
TZIELD是一种CD3导向的抗体,用于延缓3期的8岁及以上儿童和成人患者的1型糖尿病(T1D)发病
Licensor:
Provention Bio, Inc.
Approved Country/Region:
FDA
Approval time:
2022-11-18